drugset / Trial / NCT07006012
RGL-305+ Lymphoma + Exploratory Clinical Study
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is an open, prospective, dose-increasing exploratory clinical trial. To evaluate the safety, cytodynamics and initial efficacy of RGL-305 in patients with lymphoma. All enrolled lymphoma patients were required to achieve CR or PR and MRD positive after standard treatment, PR patients were required to have a Deauville score of 4, and all patients would receive RGL-305 cell reinfusion therapy.
Timeline
- Start
- 2025-04-21
- Primary completion
- 2028-03-31
- Completion
- 2031-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RGL-305 | Cell therapy | — | Intravenous |